GlassScriptPhysician profile
Vincent J Granowicz
NPI 1528057270
$2,351.18
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,522 · 2020: $580 · 2021: $250.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,238.95 | 2019-2020 | |
| Novo Nordisk INC | $360.98 | 2019-2021 | |
| Glaxosmithkline, LLC. | $139.57 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $97.67 | 2019 | |
| Gilead Sciences, INC. | $93.24 | 2019 | |
| Allergan, INC. | $87.27 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $50.99 | 2020-2021 | |
| Vivus LLC | $48.33 | 2020 | |
| Shire North American Group INC | $30.02 | 2019 | |
| Abbvie INC. | $26.83 | 2021 | |
| Merck Sharp & Dohme LLC | $23.00 | 2019 | |
| Lilly USA, LLC | $20.94 | 2020 | |
| Eisai INC. | $18.54 | 2020 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$150.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Granowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.